Literature DB >> 16547672

A prospective analysis of living-liver donation shows a high rate of adverse events.

Federica Dondero1, Oliver Farges, Jacques Belghiti, Claire Francoz, Daniele Sommacale, Francois Durand, Alain Sauvanet, Sylvie Janny, Deepak Varma, Valerie Vilgrain.   

Abstract

Donor risk is the main obstacle in the development of living-donor liver transplantation in Western countries. The knowledge of a wide and uneven range of donor morbidity has come mainly from various retrospective analyses of complications in the literature. Donor outcomes have not been prospectively analyzed. From 1995, the intra- and postoperative courses of 127 living-donor hepatectomies were prospectively analyzed and recorded. All adverse events were classified and stratified according to the extent of surgery, including 45 left-lateral sectionectomies (LLS); 25 left hepatectomies (LH), and 57 right hepatectomies (RH). There was no donor death. The overall rate of significant complications was 20%, ranging from 8% after LH to 32% after RH. The overall incidences of surgical complications, reoperations, and hospital readmissions were 8%, 3%, and 5%, respectively. However, the prospective accumulation of all adverse events revealed an overall postoperative morbidity of 51%, ranging from 32% after LH to 66% after RH. In conclusion the incidence of postoperative adverse events after living donation is nearly 50% as revealed by prospective screening. These results allow more accurate information for potential donors. This study confirms that right hepatectomy carries three times higher risk of morbidity as compared to left-sided resections, leading to reappraisal of the use of left grafts in adults.

Entities:  

Mesh:

Year:  2006        PMID: 16547672     DOI: 10.1007/s00534-005-1017-9

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  5 in total

1.  Pharmacologic prophylaxis, postoperative INR, and risk of venous thromboembolism after hepatectomy.

Authors:  Hari Nathan; Matthew J Weiss; Gerald A Soff; Michelle Stempel; Ronald P Dematteo; Peter J Allen; T Peter Kingham; Yuman Fong; William R Jarnagin; Michael I D'Angelica
Journal:  J Gastrointest Surg       Date:  2013-10-16       Impact factor: 3.452

2.  Hepatic veins as a site of clot formation following liver resection.

Authors:  Emmanuel Buc; Safi Dokmak; Magaly Zappa; Marie Helene Denninger; Dominique Charles Valla; Jacques Belghiti; Olivier Farges
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

3.  Post-operative pharmacologic thromboprophylaxis after major hepatectomy: does peripheral venous thromboembolism prevention outweigh bleeding risks?

Authors:  Srinevas K Reddy; Ryan S Turley; Andrew S Barbas; Jennifer L Steel; Allan Tsung; J Wallis Marsh; Bryan M Clary; David A Geller
Journal:  J Gastrointest Surg       Date:  2011-06-21       Impact factor: 3.452

Review 4.  Hematopoietic stem cell transplantation for non-malignant gastrointestinal diseases.

Authors:  Abdulbaqi Al-toma; Petula Nijeboer; Gerd Bouma; Otto Visser; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

5.  Russell Strong and the history of reduced-size liver transplantation.

Authors:  Guiseppe Garcea; Hajir Nabi; Guy J Maddern
Journal:  World J Surg       Date:  2009-08       Impact factor: 3.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.